Catalyst Dossier · compiled by CeliA 🧫
Medicale Corp. (MCLE)
Services-Health Services · market cap $414,400
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ODX (Osteodex) | Phase 2 | Multiple Myeloma |
| IVACFLU-A/H5N1 vaccine | Phase 3 | Avian Influenza |
| Tavokinogene Telseplasmid (tavo) | Phase 2 | Melanoma |
| Oxytocin 100 i.u. | Phase 2 | Vaginal Atrophy |
| Adoptive Cellular Therapy | Phase 3 | Cytomegalovirus Infection |
| Oxytocin 400 IU vaginal gel | Phase 2 | Vulvovaginal Atrophy |
| CMV-specific T-cells, single infusion following single positive CMV PCR result | Phase 2 | Cytomegalovirus Infection |
| Cytovir-ADV | Phase 2 | ADV Infection Post Allo-HSCT |
| Nab paclitaxel | Phase 2 | Pancreatic Cancer |
| Sevre-Long™ | Phase 3 | Opiate Dependent |
| Oxytocin | Phase 2 | Atrophy |
| FX06 | Phase 2 | Myocardial Ischemia |
| GDC 268 Lotion | Phase 3 | Acne Vulgaris |
| IVACFLU-S | Phase 3 | Influenza, Human |
| GDC-229 | Phase 3 | Bacterial Vaginosis |
| EPODURE (dermal Biopump for erythropoietin) | Phase 2 | Anemia |
| COVIVAC vaccine | Phase 2 | COVID-19 |
| Tadalafil 5mg (Male) | Phase 3 | Erectile Dysfunction |
| Glyceryl trinitrate | Phase 2 | Erectile Dysfunction |
| Osteodex | Phase 2 | Prostate Cancer Metastatic |
Price & technical context
3-month
-40.0%
6-month
-20.0%
12-month
-55.6%
52-wk range
$0.02–$0.73
vs 50-day MA
+18.8%
vs 200-day MA
-31.2%
Realized vol
285.7%
Max drawdown
-97.3%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MCLE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.